Every Form 4 that Ascentage Pharma Group International (AAPG) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AAPG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AAPG filings page.
Ascentage Pharma Group International Chief Medical Officer Yifan Zhai reported multiple equity compensation transactions involving options, restricted stock units (RSUs), and related ordinary shares of AAPG.
On May 20, 2026, entities associated with Zhai received several awards. These included options for 298,194 ordinary shares held indirectly by a spouse at an exercise price of $6.58 per share, options for 214,988 ordinary shares directly at $6.58 per share, and options for 103,364 ordinary shares directly at $8.12 per share. Multiple RSU grants were also recorded, including 298,195, 214,999, 103,365, 95,575, and 92,746 RSUs tied to one ordinary share each upon vesting.
On May 21, 2026, RSUs vested and were converted into ordinary shares. Indirectly through a spouse, 95,575 RSUs vested into the same number of ordinary shares, resulting in 1,193,569 indirectly held ordinary shares. Directly, 92,746 RSUs vested into ordinary shares, bringing direct ordinary share holdings to 405,280 shares. No sales of shares were reported; all transactions were classified as acquisitions, grants, or exercises. Additional indirect ordinary share holdings of 22,054,131 shares held by HealthQuest Pharma Limited and 14,089,111 shares held by Dajun Yang Dynasty Trust are attributed to related entities, with beneficial ownership disclaimed except for any pecuniary interest.
ASCENTAGE PHARMA GROUP INTERNATIONAL Chairman and CEO Dajun Yang reported a series of equity compensation events, primarily vesting and grants of restricted stock units (RSUs) and options, with no open-market buying or selling.
On May 21, 2026, RSUs vested and were exercised into 92,746 ordinary shares held indirectly through his spouse and 95,575 ordinary shares held directly, increasing his reported ordinary share holdings to 405,280 indirectly and 1,193,569 directly. On May 20, 2026, Yang and his spouse received multiple new RSU and option awards at a $0.00 grant price, including a direct option grant over 298,194 ordinary shares and several indirect grants to his spouse, all scheduled to vest in installments between 2026 and 2030. Additional large indirect holdings are reported in entities such as the Dajun Yang Dynasty Trust and HealthQuest Pharma Limited, with Yang disclaiming beneficial ownership except to the extent of his pecuniary interest.
Misra Veet reported acquisition or exercise transactions in this Form 4 filing.
Ascentage Pharma Group International reported a compensation-related equity grant to its Chief Financial Officer, Veet Misra. The filing shows an award of 18,584 restricted stock units (RSUs) on April 20, 2026.
Each RSU represents a contingent right to receive one Ordinary Share of the company upon vesting. According to the disclosure, these RSUs vest immediately and have no expiration date. Following this grant, the CFO directly holds 18,584 RSUs, reflecting a new equity-based incentive aligned with the company’s share performance.